Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US6706686B2 · kind B2 · utility
45Cited by
3References
50Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2002 |
| Grant date | Mar 16, 2004 |
| Priority date | — |
| Expiry date | Sep 26, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.